Keros Therapeutics, Inc. Price & Performance (KROS)

Keros Therapeutics has launched a strategic review that could result in a sale or other major transaction, following pressure from investors rapidly increasing their stakes. The company also adopted a poison pill provision to prevent hostile takeovers, aiming to protect shareholder interests during the review process. Shares surged on the news.123

Shares of Keros Therapeutics have soared after the company announced a strategic review, including possible sale or business combinations. The adoption of a shareholder rights plan, designed to deter hostile takeovers, further buoyed investor optimism. The market has reacted positively, with the stock reaching its highest level since January 2025.456

Keros Therapeutics has reported positive interim results from its lead candidate’s Phase 2 trial and secured new funding through a private placement. These developments, alongside its exploration of strategic alternatives, have strengthened the company's financial position and investor confidence, resulting in a notable stock price increase over the past week.789